Evidence map›Paper›PMID 31749018›Full record

ArticleAging clinical and experimental research2020

Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study.

Elena Rolandi, Alessandra Dodich, Samantha Galluzzi, Clarissa Ferrari, Sara Mandelli, Federica Ribaldi, Giulio Munaretto, Claudia Ambrosi, Roberto Gasparotti, Davide Violi and 8 more

Abstract readClinical Trial Protocol
PubMed Publisher
In one paragraph

Article in Aging clinical and experimental research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 3 countries.

Elena RolandiLaboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.ORCID http://orcid.org/0000-0003-0043-2471
Alessandra DodichNIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland.
Samantha GalluzziLaboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Clarissa FerrariStatistics Service, IRCCS Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Sara MandelliIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Federica RibaldiLaboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Giulio MunarettoLaboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Claudia AmbrosiDepartment of Diagnostic Imaging, Neuroradiology Unit, University of Brescia, Brescia, Italy.
Roberto GasparottiDepartment of Diagnostic Imaging, Neuroradiology Unit, University of Brescia, Brescia, Italy.
Davide VioliMillennium Sport and Fitness, 25124, Brescia, Italy.
Nicola CanessaNEtS Center, Scuola Universitaria Superiore IUSS Pavia, 27100, Pavia, Italy.
Sandro IannacconeDepartment of Clinical Neuroscience, San Raffaele Turro Hospital, 20132, Milan, Italy.
Alessandra MarconeDepartment of Clinical Neuroscience, San Raffaele Turro Hospital, 20132, Milan, Italy.
Andrea FaliniDivision of Neuroscience, Department of Neuroradiology and CERMAC, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Harald HampelAlzheimer Precision Medicine (APM), Établissements Publics à Caractère Scientifique et Technologique (E.P.S.T.), AP-HP, Pitié-Salpêtrière Hospital, Sorbonne University Clinical Research Group (GRC n°21), Boulevard de l'hôpital, 75013, Paris, France.
Giovanni B FrisoniLaboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Chiara CeramiCognitive Neuroscience Laboratory, IRCCS ICS Maugeri, 27100, Pavia, Italy.
Enrica CavedoLaboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy. enrica.cavedo@gmail.com.
Centro San Giovanni di Dio Fatebenefratelli · ITUniversity of Geneva · CHCentre National de la Recherche Scientifique · FRSan Raffaele University of Rome · ITUniversity of Brescia · ITIstituti Clinici Scientifici Maugeri · ITIstituto Universitario di Studi Superiori di Pavia · ITMario Negri Institute for Pharmacological Research · ITUniversity of Trieste · ITVita-Salute San Raffaele University · IT

Funding

Ministero della Salute GR-2011-02350494
6 · The paper itself

Abstract

backgroundAlzheimer's Disease (AD) is a multifactorial disorder driven by genetic and modifiable lifestyle risk factors. Lifestyle primary prevention initiatives may reduce the prevalence and incidence of dementia in older adults.

objectivesThe E.Mu.N.I study is a randomized controlled trial investigating the effect of multilevel non-pharmacologic interventions on cognitive performances (primary outcome) and structural and vascular brain MRI markers (secondary outcome), as well as markers of brain functional connectivity change (exploratory outcome), in older adults with subjective memory decline (SMD). Here, we present the study design and the baseline features of the sample.

methodsCognitively intact older adults with SMD, enrolled between February 2016 and June 2017, were randomly assigned to one of the 3 interventions for 1 year: Active Control Intervention (ACI), i.e., educational lessons; Partial Intervention (PI), i.e., homotaurine administration (100 mg/die) and lessons on the Mediterranean diet; Multilevel Intervention (MI), i.e., PI plus computerized cognitive training and physical exercise training.

resultsOne-hundred and twenty-eight eligible participants were enrolled (66% female; age: 68 ± 5 years). Eighty-two percent of the sample was composed of volunteers with SMD from the community. Participants were randomly allocated to the interventions as follows: ACI (N = 40), PI (N = 44), MI (N = 44). No significant differences among groups emerged on socio-demographic, clinical-neuropsychological variables and MRI markers at baseline.

conclusionsThe outcomes obtained from the E.Mu.N.I. study will clarify the efficacy of multilevel non-pharmacologic interventions on cognitive and neuroimaging markers in SMD individuals. This is a crucial step forward for the development of cost-effective non-pharmacologic primary prevention initiatives for AD.

Indexed as

MemoryAgedBrainDementiaExerciseFemaleHumansLife StyleMagnetic Resonance ImagingMaleMemory DisordersMiddle AgedRandomized Controlled Trials as TopicAlzheimer’s diseaseNeuroimagingNon-pharmacologic interventionsPrimary preventionSubjective cognitive decline

Identifiers

PMID31749018
OpenAlexW2990197319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.